Dr Reddy's Ties Up With Sanofi To Distribute Beyfortus In India

Dr Reddy's Laboratories Ltd. on Monday said it has signed a marketing agreement with Sanofi India Pvt. Ltd. to distribute Beyfortus injection, a drug used to protect children from respiratory issues.

Beyfortus is the first monoclonal antibody approved to prevent respiratory problems in infants. Under the agreement, Dr Reddy's will have exclusive distribution rights for the drug in India, the company said in a press release. The company plans to launch Beyfortus during the July-September quarter. The drug can be administered to children up to 24 months of age to protect against the respiratory syncytial virus.

Earlier, Dr Reddy's and Sanofi India had partnered to distribute Sanofi’s vaccine portfolio in India. Beyfortus received marketing authorisation from the Central Drugs Standard Control Organisation in June last year.